Akshat Jain: NEJM Group Study Demonstrates Platelet Responses in ITP Treated with Mezagitamab
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn about a recent article by David J. Kuter et al. published in NEJM, adding:
“Exciting new data in ITP treatment : a phase 2 NEJM Group study found that mezagitamab, a CD38-targeting antibody, produced rapid and sustained platelet responses, with the highest dose showing a platelet response in 91% of patients by week 16 and a safety profile similar to placebo.
Why this matters: ITP remains an area of major unmet need, and this therapy may represent a true shift from symptom control toward disease modification by targeting the immune cells driving platelet destruction.
If confirmed in phase 3, mezagitamab could meaningfully change the treatment landscape for patients who do not respond well to current options.
600 mg dose achieving a platelet response in 91% of patients by week 16 and a tolerability profile comparable to placebo.
This is especially important in ITP, where many patients still have limited durable responses to existing therapies.
By targeting CD38-expressing immune cells, mezagitamab may offer a more disease-modifying approach rather than just temporary platelet support.”
Title: A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia
Authors: David J. Kuter, Katsuhiro Miura, Andrea Patriarca, Dražen Pulanić, Atanas Radinoff, Katya Sapunarova, Antonia Syrigou, Renchi Yang, Van Anh Nguyen, Emily Skelton, Scarlett Wang, Donald L. Yee, Parth Patwari
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 18, 2026, 11:10R. Stephani Hellwege: Beyond LVEF Echocardiographic Assessment of Undifferentiated Shock
-
Sep 18, 2026, 06:48Gopal Patidar: Honoured to Contribute to the ASFA 2026 Guidelines for Therapeutic Apheresis
-
Sep 18, 2026, 05:48Julie Taylor: Navigating Tech Glitches to Deliver Engaging BBTS Presentation
-
Sep 18, 2026, 05:42Emma Copperwaite: BBTS Conference Presentation Highlights Power of Peer Support and Pushing Past Fear
-
Sep 18, 2026, 05:34Suhasini Sil: RGSSH Joins Mega Blood Donation Camp at Thyagaraj Stadium
-
Sep 18, 2026, 05:25Lisa Laun: Spleen Clears Activated Platelets to Limit Thrombosis and Inflammation
-
Sep 18, 2026, 05:16Louise St. Germain Bannon: ISTH Advocates for Enhanced Patient Safety in Blood Disorder Care
-
Sep 18, 2026, 05:08Vikas Veer: Exploring Sickle Cell Anemia at the Molecular Level
-
Sep 18, 2026, 01:35Matthew Hazell: From Platelet Refractoriness to Protecting Transplanted Organs